Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.68 |
| ▸ | CASP4 | P49662 | 1/20 | 0.67 |
| ▸ | CASP5 | P51878 | 1/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | CASP9 | P55211 | 1/20 | 0.67 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.67 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.67 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 6/20 | 0.43 |
| ▸ | STAT5A | P42229 | 2/20 | 0.43 |
| ▸ | STAT5B | P51692 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 6/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20298320 | 1.00 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL3699919 | 1.00 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL478382 | 1.00 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL12266522 | 0.92 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL13951168 | 0.92 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL12266527 | 0.92 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL30628927 | 0.90 | CASP1 (0.66) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL478250 | 0.89 | CASP1 (0.67) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL12023624 | 0.89 | CASP1 (0.67) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL21539807 | 0.88 | CASP1 (0.63) | CASP1CASP4CASP5CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100827-A1 | COMBINED ADMINISTRATION OF CYSTEINE-ASPARTIC PROTEASE INHIBITORS WITH P2Y12 RECEPTOR ANTAGONISTS PROTECTS THE HEART AGAINST MYOCARDIAL INFARCTION | THE UNIVERSITY OF SOUTH ALABAMA | 2021-04-08 | — | — | US | claimed |
| WO-2018200958-A1 | COMBINED ADMINISTRATION OF CYSTEINE-ASPARTIC PROTEASE INHIBITORS WITH P2Y12 RECEPTOR ANTAGONISTS PROTECTS THE HEART AGAINST MYOCARDIAL INFARCTION | UNIVERSITY OF SOUTH ALABAMA (US) | 2018-11-01 | — | — | WO | claimed |
| WO-2015003246-A1 | COMBINATION OF A STATIN WITH AN INFLAMMASOME INHIBITOR | MCMASTER UNIVERSITY (CA) | 2015-01-15 | — | — | WO | claimed |
| US-20230372292-A1 | TREATMENTS OF CORONAVIRUS INFECTIONS, CYTOKINE RELEASE SYNDROME, CYTOKINE STORM SYNDROME, OR DISEASES ASSOCIATED WITH EXCESSIVE ACTIVATION OF INFLAMMASOMES BY THE USE OF INHIBITORS OF INFLAMMATORY CASPASES | IPCURE S.A.S. (FR) | 2023-11-23 | — | — | US | disclosed |
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230277559-A1 | Compositions and Methods for the Treatment of Inflammation in Urological Pathology | DUKE UNIVERSITY (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4225301-A1 | TREATMENTS OF CORONAVIRUS INFECTIONS, CYTOKINE RELEASE SYNDROME, CYTOKINE STORM SYNDROME, OR DISEASES ASSOCIATED WITH EXCESSIVE ACTIVATION OF INFLAMMASOMES BY THE USE OF INHIBITORS OF INFLAMMATORY CASPASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-20230218726-A1 | TREATMENT OF VIRAL CONJUNCTIVITIS | OKOGEN, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-3558335-B1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP AID INC (CA) | 2023-04-19 | — | — | EP | disclosed |
| US-11612615-B2 | Combined administration of cysteine-aspartic protease inhibitors with P2Y12 receptor antagonists protects the heart against myocardial infarction | THE UNIVERSITY OF SOUTH ALABAMA (US) | 2023-03-28 | — | — | US | disclosed |
| EP-4138882-A1 | TREATMENT OF VIRAL CONJUNCTIVITIS | Okogen, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-1286989-B1 | Prodrug of an ICE inhibitor | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110301096-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-08 | — | — | US | disclosed |
| US-8022041-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022041-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-7417029-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417029-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | CASP1 1/4885CASP4 260/4885CASP5 185/4885 |
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | PTGS2, PTGES2, PTGES | CASP1 2492/4885CASP4 1282/4885CASP5 2571/4885 |
| US-20110301096-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | CASP1 1/4885CASP4 260/4885CASP5 185/4885 |
| US-20230372292-A1 | TREATMENTS OF CORONAVIRUS INFECTIONS, CYTOKINE RELEASE SYNDROME, CYTOKINE STORM SYNDROME, OR DISEASES ASSOCIATED WITH EXCESSIVE ACTIVATION OF INFLAMMASOMES BY THE USE OF INHIBITORS OF INFLAMMATORY CASPASES | CASP1, IL1B, PYCARD | CASP1 1/4885CASP4 19/4885CASP5 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.